title: Succinylacetone as primary marker to detect tyrosinemia type I in newborns and its measurement by newborn screening programs.
abstract: Tyrosinemia type I (TYR I) is caused by autosomal recessive fumarylacetoacetate hydrolase deficiency and is characterized by development of severe liver disease in infancy and neurologic crises. If left untreated, most patients die of liver failure in the first years of life. Intervention with medication is effective when initiated during the first month of life. This improvement in the treatment of TYR I patients influenced the decision to include TYR I in the US Secretary of the Department of Health and Human Services' (HHS) Recommended Uniform Screening Panel. However, while tyrosine is routinely measured in newborn screening (NBS) by tandem mass spectrometry (MS/MS), elevated tyrosine levels are not specific to TYR I. To improve the specificity of NBS for TYR I, several assays were developed to measure succinylacetone (SUAC) in dried blood spots (DBS). SUAC is a pathognomonic marker of TYR I, and its detection by NBS MS/MS is possible. This review of the current status of NBS for TYR I in the US is the result of discussions at the HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children about the inconsistent implementation of effective NBS for TYR I in the US. We sought to understand the different TYR I screening practices in US NBS programs. Results indicate that 50 out of 51 NBS programs in the US screen for TYR I, and a successful SUAC performance evaluation scheme is available from the Centers for Disease Control and Prevention. Programmatic and methodological barriers were identified that prevent widespread adoption of SUAC measurements in NBS laboratories. However, since SUAC detection is currently the best approach to NBS for TYR I, a further delay of the addition of SUAC measurement into NBS procedures is discouraged. SUAC measurement should improve both the false positive and false negative rate in NBS for TYR I thereby yielding the desired benefits for affected patients at no expense to the overall population served.
authors: Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States. Electronic address: vdejesus@cdc.gov.
authors: Víctor R
authors: VR
authors: De Jesús
authors: Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States.
authors: Barbara W
authors: BW
authors: Adam
authors: Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States.
authors: Daniel
authors: D
authors: Mandel
authors: Newborn Screening and Molecular Biology Branch, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States.
authors: Carla D
authors: CD
authors: Cuthbert
authors: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States; Department of Medical Genetics, Mayo Clinic, Rochester, MN 55905, United States; Department of Pediatrics, Mayo Clinic, Rochester, MN 55905, United States.
authors: Dietrich
authors: D
authors: Matern
mesh_terms: D015415:Biomarkers / Q000097:blood; D059788:Dried Blood Spot Testing / Q000379:methods / Q000592:standards; D006537:Heptanoates / Q000097:blood*; D006801:Humans; D007231:Infant, Newborn; D015997:Neonatal Screening / Q000379:methods / Q000592:standards; D011786:Quality Control; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry; D020176:Tyrosinemias / Q000097:blood* / Q000175:diagnosis*
chemical_list: D015415:Biomarkers; D006537:Heptanoates; C020804:succinylacetone
keywords: HHS Secretary's (Discretionary) Advisory Committee on Heritable Disorders in Newborns and Children; Newborn screening; Succinylacetone; Tyrosine; Tyrosinemia type I; US Recommended Uniform Screening Panel